Compounds > kw 2581
Page last updated: 2024-11-12

kw 2581

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

KW 2581: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9912111
CHEMBL ID3612355
SCHEMBL ID5707498
MeSH IDM0515617

Synonyms (18)

Synonym
kw 2581
kw-2581
kw2581
chembl3612355 ,
bdbm50116170
SCHEMBL5707498
17-diisopropylcarbamoyl-1,3,5(10),16-estratetraen-3-yl sulfamate
estra-1,3,5(10),16-tetraene-17-carboxamide, 3-((aminodsulfonyl)oxy)-n,n-bis(1-methylethyl)-
c38u4wz67t ,
unii-c38u4wz67t
284045-56-3
[(8s,9s,13s,14s)-17-[di(propan-2-yl)carbamoyl]-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-yl] sulfamate
3-((aminosulfonyl)oxy)-n,n-bis(1-methylethyl)estra-1,3,5(10),16-tetraene-17-carboxamide
(3as,3bs,9bs,11as)-1-(bis(propan-2-yl)carbamoyl)-11a-methyl-3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta(a)phenanthren-7-yl sulfamate
((8s,9s,13s,14s)-17-(di(propan-2-yl)carbamoyl)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta(a)phenanthren-3-yl) sulfamate
estra-1,3,5(10),16-tetraene-17-carboxamide, 3-((aminosulfonyl)oxy)-n,n-bis(1-methylethyl)-
(8s,9s,13s,14s)-17-(diisopropylcarbamoyl)-13-methyl-7,8,9,11,12,13,14,15-octahydro-6h-cyclopenta[a]phenanthren-3-yl sulfamate
STARBLD0038656

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies in the same rat model demonstrated that more than 90% inhibition of STS activity in tumors was necessary to induce tumor shrinkage."( A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.
Akinaga, S; Anazawa, H; Ishida, H; Kuwabara, T; Li, PK; Murakata, C; Nakata, T; Sato, N; Shiotsu, Y; Suzuki, M; Takebayashi, M; Tanaka, H; Terasaki, Y, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Steryl-sulfataseHomo sapiens (human)IC50 (µMol)0.00400.00010.40717.6000AID1243902
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.00400.00200.02680.1000AID1243902
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.00400.00200.69046.0000AID1243902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
steroid catabolic processSteryl-sulfataseHomo sapiens (human)
female pregnancySteryl-sulfataseHomo sapiens (human)
epidermis developmentSteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
steryl-sulfatase activitySteryl-sulfataseHomo sapiens (human)
sulfuric ester hydrolase activitySteryl-sulfataseHomo sapiens (human)
metal ion bindingSteryl-sulfataseHomo sapiens (human)
arylsulfatase activitySteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
lysosomeSteryl-sulfataseHomo sapiens (human)
endosomeSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulumSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum lumenSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum membraneSteryl-sulfataseHomo sapiens (human)
Golgi apparatusSteryl-sulfataseHomo sapiens (human)
plasma membraneSteryl-sulfataseHomo sapiens (human)
membraneSteryl-sulfataseHomo sapiens (human)
intracellular membrane-bounded organelleSteryl-sulfataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1243902Inhibition of recombinant human STS transfected in CHO cells using MUS as substrate after 30 mins by fluorescence assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis of bicoumarin thiophosphate derivatives as steroid sulfatase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.552017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
methylnitrosourea
Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.		2.0310N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
estrone-3-o-sulfamate
estrone-3-O-sulfamate: a steroid sulfatase inhibitor		3.5820
tamoxifen
[no description available]		2.0310stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		2.031017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
irosustat
irosustat: Antineoplastic Agents, Hormonal; a tricyclic sulfamate ester; structure in first source		2.7330
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		4.0540benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		03.6530
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.6530
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310